Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial (CREST-2)
Aims: The purpose of this randomized trial is to determine if the incidence of stroke or death differs between subjects with high-grade asymptomatic carotid stenosis who receive intensive medical management alone, as compared to subjects who receive intensive medical management in combination with carotid artery stenting (CAS). The primary endpoint is stroke or death within 44 days after randomization or ipsilateral ischemic stroke thereafter, up to the 4-year follow-up time point.
Principal Investigator: William Ares, MD
NorthShore Project Number: EH22-019
Contact: Call 847.570.4224 with questions regarding this study.
Open to enrollment: Yes
Non-blinded Data Collection Pilot Study of Acute Stroke Using the BRAINPULSE™
Aims: The purpose of this pilot study is to collect data from patients experiencing stroke using the BrainPulse device. In the 2nd (current) phase of the study, data will be collected on two groups of patients: Those with Large Vessel Occlusion (LVO) acute stroke and non-LVO acute stroke. The data collected from the BrainPulse will be compared across these study groups in an attempt to distinguish stroke from other non-stroke conditions that present with similar symptoms and LVO from non-LVO types of strokes. Further assessments will also be made to evaluate if the BrainPulse can identify the presence of stroke.
Principal Investigator: Shakeel Chowdhry, MD
NorthShore Project Number: EH19-084
Contact: Call 847.570.4224 with questions regarding the study
Open to enrollment: Yes
Phase 3, Randomized, Double-Blind, Parallel-Group, PlaceboControlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack LIBREXIA-STROKE
Aims: The main objective of this study is to evaluate if milvexian reduces the risk of ischemic stroke as compared with placebo, to evaluate if milvexian reduces the risk of cardiovascular disease, myocardial infarction, or ischemic stroke, as compared with placebo, and to evaluate if milvexian reduces the risk of ischemic stroke in the first 90 days compared with placebo.
Principal Investigator: Fulvio Roberto Gil, MD
NorthShore Project Number: EH22-478
Contact: Call 847.570.1864 with questions regarding the study
Open to enrollment: Yes
THUNDER: Acute Ischemic Stroke Study with the Penumbra System® including Thunderbolt™ Aspiration Tubing
Aims: The objective of this study is to demonstrate the safety and efficacy of the Penumbra System including Thunderbolt Aspiration Tubing in patients with acute ischemic stroke secondary to large vessel occlusion, who are eligible for mechanical thrombectomy. The primary efficacy and safety endpoints are angiographic revascularization of the occluded target vessel at immediate post-procedure as defined by mTICI 2b or higher and occurrence of symptomatic intracranial hemorrhages (sICH) at 24 hours.
Principal Investigator: William Ares, MD
NorthShore Project Number: EH23-219
Contact: Call 847.570.4224 with questions regarding the study
Open to enrollment: Yes